Dr. Kurt R Oettel MD
Hematologist-Oncologist | Hematology & Oncology
1836 South Ave La Crosse WI, 54601About
Dr. Kurt Oettel is a hematologist oncologist practicing in La Crosse, WI. Dr. Oettel specializes in the diagnosis, treatment and prevention of blood diseases such as anemia, hemophilia, sickle-cell disease, leukemia and lymphoma. Hematologist Oncologists are also trained in the study of cancer and its attack on other organs.
Education and Training
Univ of Wi Med Sch, Madison Wi 1995
New Jersey College of Dentistry 1995
Board Certification
Internal MedicineAmerican Board of Internal MedicineABIM- Medical Oncology
Provider Details
Expert Publications
Data provided by the National Library of MedicineClinical Trials
- Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
- S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
- Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
- S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
- Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
- S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
- Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
- Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
- Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
- S0820, Adenoma and Second Primary Prevention Trial
- Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
- Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
- Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
- Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
- Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
- Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
- Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
- Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Treatments
- Anemia
- Breast Cancer
- Lung Cancer
- Colon Cancer
- Aerolase® Technologies
- Extra Corporeal Shockwave Therapy
Dr. Kurt R Oettel MD's Practice location
Dr. Kurt R Oettel MD's reviews
Write ReviewRecommended Articles
- How Dogs Are Helping with Lymphoma Research
According to the Cornell Chronicle (CC), Cornell and Tufts University have received a huge grant for the study of human lymphoma, using a humane approach to test on dogs.The dogs in the study will already have lymphoma and it’s hoped they’ll be cured in the process of this research study.There...
- Dreams Do Come True: 9-year-old Baseball Fanatic Signed Onto Team
Like most young baseball fans, John “Parker” Staples' room is covered in memorabilia from his favorite team, the Washington Nationals, but unlike most kids, Parker's room is at the University of Virginia Children's Hospital.John “Parker” Staples, is nine-year old who was diagnosed with...
- Treatment Update for Hodgkin Lymphoma
Over time, research has uncovered ways of treating Hodgkin lymphoma (HL) to produce an 80% to 90% cure rate. For the remaining 10% to 20% who are either resistant to the primary treatment or have relapsed, their cancer can still be fatal.The standard care for those not yet cured has been a two-step...
- Exercise Proven to Help Lymphoma Patients
People always say that exercise is the best medicine. It's been proven through many years of research that regular exercise is really important to maintain a healthy body and mind. Doctors are always reminding their patients of the benefits of physical exercise and the power it holds to fight...
- John Quinones Teams Up With Survivors For Leukemia and Lymphoma Society
Many cancer patients suffer in silence, with the public being largely unaware of the different types of cancer and how they affect patients. Most people obviously know that cancer is well, a bad thing, but there is a lot of nuance and important information that is lost on the common citizen. Most...
- Make-A-Wish Makes a Movie Star
Through their fundraising, on average in the United States and its territories, Make-A-Wish is able to grant the wish of a child every 34 minutes.How was it started?The Make-A-Wish Foundation started with the wish of one 7-year-old boy’s wish in 1980. Chris Grecius, who had leukemia, wanted to be...
Nearby Providers
- Dr. John P Farnen MD1836 South Ave La Crosse WI 54601
- Dr. Lori J Rosenstein M.D.1836 SOUTH AVE LA CROSSE WI 54601
- Dr. Wayne A Bottner MD1836 South Ave La Crosse WI 54601
- Dr. Benjamin M Parsons D.O.1836 SOUTH AVE LA CROSSE WI 54601
- Dr. David Edward Marinier M.D.1836 South Ave La Crosse WI 54601
- Dr. Michael O Ojelabi M.D1836 South Ave La Crosse WI 54601